Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month minocycline and ofloxacin

Indian Journal of Leprosy

Volumn 80, Issue 4, 2008, Pages 331-344

  Katoch, K ^a   Katoch, V M ^b   Natarajan, M ^a   Gupta, U D ^c   Sharma, V D ^b   Singh, H B ^b  

^a Model Rural Health Research Unit   (India)

^b GOVERNMENT OF INDIA   (India)

^c Animal Experimentation Facility

Author keywords

FDT; MB leprosy; MDT; Minocycline; Ofloxacin

Indexed keywords

CLOFAZIMINE; CORTICOSTEROID; DAPSONE; MINOCYCLINE; OFLOXACIN; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LEPROSY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; REVERSAL REACTION; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; ANIMALS; BIOPSY; DNA, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; LEPROSTATIC AGENTS; LEPROSY, MULTIBACILLARY; MALE; MICE; MIDDLE AGED; MINOCYCLINE; MYCOBACTERIUM LEPRAE; OFLOXACIN; POLYMERASE CHAIN REACTION; RECURRENCE; RNA, RIBOSOMAL; YOUNG ADULT;

EID: 71949088990     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Becx-Bleumink M (1992). Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Centre (ALERT) Ethiopia; practical difficulties in diagnosing relapses, operational procedures and criteria for diagnosing relapses. Int J Lepr Other Mycobact Dis. 60:421-435.
2. Becx-Bleumink M and Berhe D (1992). Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experiences in leprosy control program of All Africa Leprosy and Rehabilitation Training Centre(ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 60: 173-184.
3. Cellona RV, Balagon MVF, dela Cruz EC et al (2003). Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary leprosy patients. Int J Lepr Other Mycobact Dis. 71: 308-319.
4. Desikan KV and Venkataramaniah HN (1976). A modified method of harvesting M. leprae from the foot-pads of mice. Lepr India. 48:157-162.
5. Ganapati R, Pai VV, Shroff HJ et al (1997). Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions. Int J Lepr Other Mycobact Dis. 65:264-266. (Pubitemid 27323485)
6. Gelber RH, Balagon MVF and Cellona RV (2004). The relapse rate in MB leprosy patients treated with 2 - years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis. 72:493-500.
7. Girdhar BK, Girdhar A and Kumar A (2000). Relapses in multibacillary leprosy patients : effect of length of therapy. Lepr Rev. 71:144-153. (Pubitemid 30465827)
8. Gupta UD, Katoch K, Singh HB et al (2000). Assessment of viability by normal mouse foot-pad and bacillary bioluminescence in/ assay in multibacillary cases treated with an MDT regimen using conventional as well as newer drugs minocycline and ofloxacin. Indian J Lepr. 72:437-442. (Pubitemid 32111800)
9. Hartskeerl RA, De Wit MYL and Klaster PR (1989). Polymerase chain reaction for the detection of Mycobacterium leprae. J Gen Microbiol. 135: 2357-2364. (Pubitemid 19238439)
10. Iyer CGS, Balakrishnan S and Ramu G (1977). A comparison of low and conventional dosages of dapsone in the treatment of lepromatous leprosy. Lepr India. 49: 372-386. (Pubitemid 8227734)
11. Jamet P, Ji B and the Marchoux Chemotherapy Study Group (1995). Relapse rate after long-term follow-up of multibacillary patients treated by WHO multidrug regimen. Int J Lepr Other Mycobact Dis. 63:195-201.
12. Katoch K, Katoch VM, M Natrajan et al (2000). Chemotherapy trials in MB leprosy using conventional and newer drugs, pefloxacin and minocyline. Indian J Dermatol Venerol Leprol. 66: 18-25.
13. Katoch VM, Katoch K, Ramanathan U et al (1989). Effect of chemotherapy on viability of Mycobacterium leprae as determined by ATP content, morphological index, and FDA-EB fluorescent staining. Int J lepr Other Mycobact Dis. 57:615-621. (Pubitemid 19244228)
14. Katoch VM, Kanaujia GV, Shivannavar CT et al (1992). rRNA gene based probes for early diagnosis and epidemiology of leprosy. Quad di Co-oper Sanit health Co-op papers. 12:163-166.
15. National Leprosy Elimination Programme (2008). Available at: www.nlep.nic.in.
16. Norman G, Joseph G and Richard J (2004). Relapses in multibacillary patients treated with multi-drug therapy until smear negativity. Findings after twenty years. Int J Lepr Other Mycobact Dis. 72: 1-7. (Pubitemid 38747454)
17. Poojabylaiah M, Marne RB, Varikkodan R et al (2008). Relapses in multibacillary leprosy patients after multi-drug therapy. Lepr Rev. 79:320-324.
18. Report of IAL workshop on reactions in leprosy (2003). Indian J Lepr. 75:295-303.
19. Sharma RK, Shivannavar CT, Katoch K et al (1997). Microdensitometric scanning procedure for quantitative assessment of hybridization of rRNA targeting probes in leprosy Acta Leprol. 10:213-217.
20. Shepard CC (1960). The experimental disease that follows the injection of human leprosy bacilli into foot-pads of mice. J Exp Med. 112:445-454.
21. Singh HB, Katoch K, Natrajan M et al (1999). Effect of treatment on PCR positivity in multibacillary leprosy patients treated with conventional and newer drugs ofloxacin and minocycline. Acta Leprol. 11:179-182.
22. THELEP (1987). Subcommittee on clinical trials of Scientific Working Group on chemotherapy of leprosy (THELEP). Scientific Working Group UNDP/ World Bank/WHO special programme for research in tropical diseases. THELEP controlled clinical drug trials. Int J Lepr Other Mycobact Dis. 55.(Suppl):864-871.
23. WHO Expert Committee on leprosy (1998). Seventh report, Geneva, WHO. World Health Organ Tech Rep Ser. 874: 1-43.
24. World Health Organization (2001). Risk of relapse in leprosy. The leprosy Unit Division of Tropical Diseases. Geneva, WHO document. WHO/CTD/Lep/94.1
25. World Health Organization (2002). Report of the forth meeting of TAG on Elimination of leprosy. Geneva, WHO.